TrialsgrambetaRCTs are beautiful

SYGMA 1

2018

Symbicort Given As Needed in Mild Asthma 1

In 3,849 patients with mild asthma, PRN budesonide-formoterol reduced severe exacerbations compared with PRN terbutaline.

Result

Efficacy: Well-controlled asthma weeksOR 1.14 (95% CI 1.00-1.30) · P = 0.046

Below 1 favours PRN terbutaline, above 1 favours PRN budesonide-formoterol.

Event rates
Absolute difference
3.3 points

The absolute difference is derived from the event rates.

Also reported: Severe exacerbation rate reduced 64% vs as-needed SABA (RR 0.36, 95% CI 0.27–0.49).

Original publication
Subtopic
PRN ICS-formoterol
Design
Multicentre RCT
Relevance
Practice-defining: a trial the guidelines cite as evidence.
Source
O'Byrne PM, et al. N Engl J Med. 2018;378(20):1865-1876.doi 10.1056/NEJMoa1715274

Discussion & critique

Foundational evidence for GINA's recommendation against SABA-only therapy; PRN ICS-formoterol is the new standard for mild asthma.